What Happened?
Shares of health insurance company Oscar Health (NYSE:OSCR) fell 3.1% in the morning session after the stock continued a sharp decline from the previous session, which was fueled by multiple analyst downgrades and broader weakness in the healthcare plans sector.
The health insurance technology company saw its stock fall after analysts from both Wells Fargo and UBS took a more cautious stance. Wells Fargo downgraded the stock to underweight and significantly cut its price target, citing concerns about rising costs and inadequate pricing for its 2025 plans. Similarly, UBS moved its rating to sell, anticipating a notable decline in exchange enrollments in 2026. This negative sentiment from Wall Street followed a significant drop in the prior day's trading, where the stock plunged amid high trading volume. The downward pressure reflected broader market concerns for the healthcare sector, adding to the challenges faced by the company.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Oscar Health’s shares are extremely volatile and have had 60 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 7 days ago when the stock dropped 5% on the news that Wells Fargo downgraded the stock and slashed its price target. The financial institution lowered its rating on the health insurer to "Underweight" from "Equal Weight" and cut its price target to $10 from $16. This move reflects increasing concerns about the company's ability to navigate challenging market dynamics. Wells Fargo's analysis pointed to rising "exchange acuity," a term that refers to a trend of less healthy individuals enrolling in plans, which could negatively impact pricing strategies for 2025. The firm believes Oscar's current pricing model may not be adequate to cover the rising cost trends, leading to limited visibility for the company's performance in the near future. This downgrade follows a recent trend of cautious sentiment from Wall Street, including a new "Underweight" rating from Barclays in early July, which cited potential policy risks that could hinder growth.
Oscar Health is down 0.5% since the beginning of the year, and at $13.49 per share, it is trading 42% below its 52-week high of $23.27 from September 2024. Investors who bought $1,000 worth of Oscar Health’s shares at the IPO in March 2021 would now be looking at an investment worth $387.50.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.